207 related articles for article (PubMed ID: 16336753)
1. Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
Chua YJ; Cunningham D
Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S81-8. PubMed ID: 16336753
[TBL] [Abstract][Full Text] [Related]
2. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies.
Zhang W; Gordon M; Lenz HJ
Ann Med; 2006; 38(8):545-51. PubMed ID: 17438669
[TBL] [Abstract][Full Text] [Related]
3. A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
Jackson C; Cunningham D
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S8-15. PubMed ID: 18361806
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
Jean GW; Shah SR
Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibition induces trichomegaly.
Dueland S; Sauer T; Lund-Johansen F; Ostenstad B; Tveit KM
Acta Oncol; 2003; 42(4):345-6. PubMed ID: 12899508
[No Abstract] [Full Text] [Related]
6. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab: an IgG(1) monoclonal antibody for the treatment of epidermal growth factor receptor-expressing tumours.
Humblet Y
Expert Opin Pharmacother; 2004 Jul; 5(7):1621-33. PubMed ID: 15212612
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab (Erbitux)--an emerging targeted therapy for epidermal growth factor receptor-expressing tumours.
Ng M; Cunningham D
Int J Clin Pract; 2004 Oct; 58(10):970-6. PubMed ID: 15587777
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).
Correale P; Marra M; Remondo C; Migali C; Misso G; Arcuri FP; Del Vecchio MT; Carducci A; Loiacono L; Tassone P; Abbruzzese A; Tagliaferri P; Caraglia M
Eur J Cancer; 2010 Jun; 46(9):1703-11. PubMed ID: 20399639
[TBL] [Abstract][Full Text] [Related]
10. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
Venook AP
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.
Chung KY; Shia J; Kemeny NE; Shah M; Schwartz GK; Tse A; Hamilton A; Pan D; Schrag D; Schwartz L; Klimstra DS; Fridman D; Kelsen DP; Saltz LB
J Clin Oncol; 2005 Mar; 23(9):1803-10. PubMed ID: 15677699
[TBL] [Abstract][Full Text] [Related]
12. Highlights from: 42nd Annual Meeting of the American Society of Clinical Oncology.
Reddy GK; Guputa M; Tyagi P
Clin Colorectal Cancer; 2006 Sep; 6(3):184-8. PubMed ID: 17026786
[No Abstract] [Full Text] [Related]
13. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.
Caponigro F; Formato R; Caraglia M; Normanno N; Iaffaioli RV
Curr Opin Oncol; 2005 May; 17(3):212-7. PubMed ID: 15818163
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
[TBL] [Abstract][Full Text] [Related]
16. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
17. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer.
Hebbar M; Wacrenier A; Desauw C; Romano O; Cattan S; Triboulet JP; Pruvot FR
Anticancer Drugs; 2006 Aug; 17(7):855-7. PubMed ID: 16926635
[TBL] [Abstract][Full Text] [Related]
18. Epithelial growth factor receptor interacting agents.
Baselga J; Albanell J
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1041-63. PubMed ID: 12512382
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
20. Colorectal cancer: Irinotecan therapy-following a trail of breadcrumbs?
Goldberg RM; O'Neil BH
Nat Rev Gastroenterol Hepatol; 2009 Sep; 6(9):507-9. PubMed ID: 19713983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
